Fairmount Funds Management LLC
CIK
1802528
Location
WEST CONSHOHOCKEN, PA
Portfolio Value
Mid
$1,512,967,792
Diversification
Diversified
Filing Date
Global Rank
#1,934
/ 8,798
▼ 215
· as of Jun 2026
Top Industry
Biotechnology
100.0%
3Y Alpha vs SPY
+27.0%
Period ended 3 months ago
Filed Aug 14, 2026 · 57d
26 quarters · since Mar 2020
Clone Performance
Build a hypothetical price-return history from this filer's public 13F holdings.
View clone backtestPortfolio Concentration
12 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Top Position
23.3%
+7.0 pts
Top 5
75.4%
+0.6 pts
Top 10
97.6%
+0.5 pts
HHI
1,391
Diversified+159
Portfolio Trend
26 quarters · across all stocks
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $1,512,967,792 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
1 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| VRDN | Viridian Therapeutics, Inc.\DE | +1,176,470 | 5,090,928 | $93,520,347 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reducedNo qualifying positions this quarter.
New Positions
Positions the filer opened this quarter
1 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| FTH | Faeth Therapeutics, Inc. | 722,020 | $18,050,500 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited
1 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| SYRE | Spyre Therapeutics, Inc. | 4,018,101 | $202,673,014 | |
| No positions match the current search. | ||||
12 tracked positions ·
$1,512,967,792 total
· filing declares
12 positions · $1,512,967,797
· as of Jun 30, 2026
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| ORKA |
Oruka Therapeutics, Inc.
Healthcare
|
Held | 3,705,262 | $352,629,784 | 23.31% | |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
Healthcare
|
Held | 2,537,191 | $247,325,378 | 16.35% | |
| DMRA |
Damora Therapeutics, Inc.
Healthcare
|
Held | 8,713,000 | $226,625,130 | 14.98% | |
| COGT |
Cogent Biosciences, Inc.
Healthcare
|
Held | 5,503,418 | $212,982,276 | 14.08% | |
| JBIO |
Jade Biosciences, Inc.
Healthcare
|
Held | 4,553,494 | $101,178,636 | 6.69% | |
| ELVN |
Enliven Therapeutics, Inc.
Healthcare
|
Held | 1,855,644 | $94,173,933 | 6.22% | |
| VRDN |
Viridian Therapeutics, Inc.\DE
Healthcare
|
Added | 5,090,928 | $93,520,347 | 6.18% | |
| ZBIO |
Zenas BioPharma, Inc.
Healthcare
|
Held | 2,359,025 | $59,872,054 | 3.96% | |
| CBIO |
Crescent Biopharma, Inc.
Healthcare
|
Held | 2,747,866 | $49,461,588 | 3.27% | |
|
|
Held | 298,647 | $39,639,416 | 2.62% | ||
| FTH |
Faeth Therapeutics, Inc.
Healthcare
|
NEW | 722,020 | $18,050,500 | 1.19% | |
| IKT |
Inhibikase Therapeutics, Inc.
Healthcare
|
Held | 8,625,000 | $17,508,750 | 1.16% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.